CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionP/E ratio is 660×, higher than 95% of its Biotechnology peers (median 32.39×)
- FinancialsAltman Z-Score 3.52: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.37%
Annual Rate
CNY 0.02Paid unknown
Payout Ratio
134.1%High
Last Ex-Dividend
Jun 3, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.67BCNY397.07M · vs all stocks (USD)
Trailing P/E
660.00xvs Biotechnology peers
Revenue (TTM)
271.53MCNY40.33M · vs all stocks (USD)
Profit Margin
2.51%vs Biotechnology peers
Beta
0.5160xvs all stocks
52-Week Change
-46.31%vs all stocks
Forward Annual Dividend Yield
0.37%vs all stocks
Market Capitalization
2.67BCNY397.07M · vs all stocks (USD)
Enterprise Value
2.60BCNY386.43M · vs all stocks (USD)
Trailing P/E
660.00xvs Biotechnology peers
Price to Sales (TTM)
9.85xvs Biotechnology peers
Price to Book (MRQ)
2.99xvs Biotechnology peers
Enterprise to Revenue
9.58xvs Biotechnology peers
Enterprise to EBITDA
54.76xvs Biotechnology peers
Gross Margin
55.80%vs Biotechnology peers
Profit Margin
2.51%vs Biotechnology peers
Operating Margin
-7.14%vs Biotechnology peers
Return on Assets (TTM)
0.59%vs Biotechnology peers
Return on Equity (TTM)
1.04%vs Biotechnology peers
Revenue (TTM)
271.53MCNY40.33M · vs all stocks (USD)
Revenue per Share (TTM)
0.5920CNYUpdated Aug 20, 2026Quarterly Revenue Growth
16.80%vs Biotechnology peers
Gross Profit (TTM)
172.37MCNY25.60M · vs all stocks (USD)
EBITDA (TTM)
64.84MCNY9.63M · vs all stocks (USD)
Net Income (TTM)
6.83MCNY1.01M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-12.93%vs Biotechnology peers
Operating Cash Flow (TTM)
55.76MCNY8.28M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-98.92MCNY-14.69M · vs all stocks (USD)
Forward Annual Dividend Rate
0.0200CNYUpdated Aug 20, 2026Forward Annual Dividend Yield
0.37%vs all stocks
Trailing Annual Dividend Rate
0.0250CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
0.37%vs all stocks
Payout Ratio
134.15%vs Biotechnology peers
Minority Interest (Equity)
3.60MCNYFY2025 · Dec 31, 2025Revenue
263.23MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
94.81MCNYFY2025 · Dec 31, 2025Gross Profit
168.42MCNYFY2025 · Dec 31, 2025Operating Income
26.44MCNY3.93M · vs all stocks (USD)
Pre-tax Income
13.29MCNYFY2025 · Dec 31, 2025Income Tax Expense
-2.18MCNYFY2025 · Dec 31, 2025Net Income
15.47MCNYFY2025 · Dec 31, 2025EBIT
39.78MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
64.84MCNYFY2025 · Dec 31, 2025Research & Development
41.45MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
42.14MCNYFY2025 · Dec 31, 2025Other Operating Expenses
1.85MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
10.21MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
26.49MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.0300CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0300CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
458.11MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
458.11MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
15.47MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-1.72MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-1.57MCNYFY2025 · Dec 31, 2025Free Cash Flow
-18.29MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
335.98MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
15.47MCNYFY2025 · Dec 31, 2025Other Non-cash Items
27.20MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-20.55MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-23.69MCNYFY2025 · Dec 31, 2025Capital Expenditures
-16.72MCNYFY2025 · Dec 31, 2025Net Acquisitions
359.14KCNYFY2025 · Dec 31, 2025Purchase of Investments
-17.00MCNYFY2025 · Dec 31, 2025Sale of Investments
25.77MCNYFY2025 · Dec 31, 2025Other Investing Activity
46.10MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
38.51MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
26.69MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-40.99MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-13.86MCNYFY2025 · Dec 31, 2025Other Financing Charges
640.00KCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-27.52MCNYFY2025 · Dec 31, 2025Shares Outstanding
405.07MSharesUpdated Aug 20, 2026Float Shares
150.35MSharesUpdated Aug 20, 2026% Held by Insiders
63.36%vs all stocks
% Held by Institutions
0.84%vs all stocks
Total Cash (MRQ)
599.66MCNY89.06M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.48CNYUpdated Aug 20, 2026Total Debt (MRQ)
461.49MCNY68.54M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.5131xvs Biotechnology peers
Current Ratio (MRQ)
7.29xvs Biotechnology peers
Book Value per Share (MRQ)
2.21CNYUpdated Aug 20, 2026Total Assets
1.52BCNY226.43M · vs all stocks (USD)
Total Current Assets
817.81MCNYFY2025 · Dec 31, 2025Total Liabilities
616.87MCNYFY2025 · Dec 31, 2025Total Non-current Assets
706.73MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
456.16MCNYFY2025 · Dec 31, 2025Total Current Liabilities
160.70MCNYFY2025 · Dec 31, 2025Cash
335.31MCNYFY2025 · Dec 31, 2025Cash Equivalents
57.53MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
392.84MCNYFY2025 · Dec 31, 2025Other Short-term Investments
235.30MCNYFY2025 · Dec 31, 2025Accounts Receivable
110.21MCNYFY2025 · Dec 31, 2025Inventory
54.77MCNYFY2025 · Dec 31, 2025Accounts Payable
72.96MCNYFY2025 · Dec 31, 2025Short-term Debt
34.55MCNYFY2025 · Dec 31, 2025Other Current Liabilities
2.14MCNYFY2025 · Dec 31, 2025Long-term Debt
413.00MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
2.08MCNYFY2025 · Dec 31, 2025Common Stock (Book)
405.07MCNYFY2025 · Dec 31, 2025Retained Earnings
160.24MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
907.68MCNY134.81M · vs all stocks (USD)
52-Week Low
5.55CNYUpdated Aug 20, 202652-Week High
14.15CNYUpdated Aug 20, 202652-Week Change
-46.31%vs all stocks
Beta
0.5160xvs all stocks
50-Day MA
6.25CNYUpdated Aug 20, 2026200-Day MA
8.40CNYUpdated Aug 20, 2026Avg 10-Day Volume
7.64MSharesUpdated Aug 20, 2026Avg 30-Day Volume
8.15MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
0.0100CNYUpdated Aug 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
P/E ratio is 660×, higher than 95% of its Biotechnology peers (median 32.39×)Significant
P/E ratio: 660Industry median: 32.39Industry P95: 210.5Peers compared: 261
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.56Profit Margin: 0.03
Financial Health
Altman Z-Score 3.52: safe zoneNotable
Altman Z-Score: 3.52
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Blau Farmacêutica S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Enanta Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
NIOX Group plc
Tier 1ProductionApproval-Gated PipelineRule
Abeona Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Emergent BioSolutions Inc.
Tier 1ProductionApproval-Gated PipelineRule
Foresee Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
DiaMedica Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Kontour Xi'an Medical Technology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sutro Biopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Atea Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule